EDEN PRAIRIE, Minn., March 05, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced that it will participate in the upcoming Oppenheimer 35th Annual Healthcare Conference MedTech & Services Conference on Wednesday, March 19, 2025.
NeuroOne CEO Dave Rosa will host a virtual corporate presentation at 9:20 a.m. eastern time on Wednesday, March 19, 2025, followed by one-on-one meetings, which can be requested through Oppenheimer. To join live or view a replay of the webcast, please visit this link or the events page on NeuroOne’s investors relations website.
About NeuroOne
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit www.nmtc1.com.
IR Contact
Chris Donovan
MZ Group – MZ North America
This email address is being protected from spambots. You need JavaScript enabled to view it.
(914) 352-5853
| Last Trade: | US$0.69 |
| Daily Change: | 0.03 4.79 |
| Daily Volume: | 469,379 |
| Market Cap: | US$21.400M |
April 23, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
